Bloomberg Intelligence Warner Bros Reopens Talks as Paramount Signals Higher Bid
6 snips
Feb 17, 2026 
Jeffrey Langbaum, senior U.S. REIT analyst who focuses on office and senior housing. Sam Fazeli, pharmaceuticals analyst covering biotech trials. Mandeep Singh, head of global tech research on AI and defense. They discuss Warner Bros/Paramount/Netflix deal dynamics. They cover Anthropic’s Pentagon contract and AI guardrails. They explore Moderna/Merck melanoma trial developments and office leasing trends driven by AI.
AI Snips
Chapters
Books
Transcript
Episode notes
Paramount's Offer Masks Huge Leverage Risk
- Paramount's $30/share proposal includes assuming sizeable fees and bridge loans to make the bid more attractive.
- Stephen Flynn warns combined pro forma leverage could exceed 7x without clear, timely synergy delivery.
Use Cash Flow To Convince Rating Agencies
- Rating agencies will give companies time to hit deleveraging targets but expect evidence of progress.
- Use free cash flow commitments to prioritize debt reduction and communicate clear timelines to ratings agencies.
Split Capital Can Secure Better Ratings
- Structuring debt with secured tranches can win investment-grade treatment while leaving unsecured debt as high-yield.
- Flynn compares Charter's split capital approach as a possible precedent for deal financing.
